ETF Holdings Breakdown of APGE

Stock NameApogee Therapeutics, Inc. Common Stock
TickerAPGE(USD) NASDAQ
TYPECommon Stock
CountryUSA

News associated with APGE

Analyzing Apogee Therapeutics (NASDAQ:APGE) and Zura Bio (NASDAQ:ZURA)
Zura Bio (NASDAQ:ZURA – Get Free Report) and Apogee Therapeutics (NASDAQ:APGE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership. Profitability This table compares Zura Bio and […] - 2025-05-06 05:30:46
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $92.17
Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) has earned an average recommendation of “Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock in the […] - 2025-04-21 05:14:46
KLP Kapitalforvaltning AS Acquires Shares of 5,000 Apogee Therapeutics, Inc. (NASDAQ:APGE)
KLP Kapitalforvaltning AS bought a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 5,000 shares of the company’s stock, valued at approximately $226,000. Other large investors have also recently made changes to their […] - 2025-04-08 07:32:50
Apogee Therapeutics, Inc. (NASDAQ:APGE) Position Reduced by Bank of New York Mellon Corp
Bank of New York Mellon Corp lowered its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 1.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 110,827 shares of the company’s stock after selling 1,774 shares during the period. Bank of New York Mellon Corp’s holdings in Apogee Therapeutics were worth $5,020,000 […] - 2025-03-18 07:09:01
Apogee Therapeutics (NASDAQ:APGE) Now Covered by Citigroup
Citigroup began coverage on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a research note released on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $95.00 target price on the stock. A number of other brokerages have also recently issued reports on APGE. Canaccord Genuity Group assumed coverage on Apogee […] - 2025-03-14 07:48:55
Apogee Therapeutics (NASDAQ:APGE) Earns Outperform Rating from Wedbush
Wedbush reaffirmed their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a research note issued to investors on Tuesday morning,RTT News reports. The firm currently has a $90.00 price objective on the stock. Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity Group assumed coverage […] - 2025-03-12 06:56:50
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Handelsbanken Fonder AB
Handelsbanken Fonder AB trimmed its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 14.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,500 shares of the company’s stock after selling 1,300 shares during the period. Handelsbanken Fonder AB’s holdings […] - 2025-03-04 08:46:55
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have been given a consensus rating of “Buy” by the seven research firms that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on […] - 2025-03-04 06:47:02
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) PT at $89.71
Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have been given an average rating of “Buy” by the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have covered the stock […] - 2025-02-05 06:06:46

APGE institutional holdings

The following institutional investment holdings of APGE have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 15,404USD 582,425
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 6,706USD 253,554 6.8%
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 21,688USD 820,023
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 21,688USD 820,023 6.8%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 82USD 3,100
Total =65,568 USD 2,479,125
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.